A drug industry sponsored paper further underscores the abuses by hospitals of the 340B program.
A Deloitte report focuses on how drug companies can get more connected with patients using their products.
A Magellan report shows that specialty drug costs are a big issue for Medicaid too.
Contrary to the most commonly cited cost, a new study at JAMA Internal Medicine finds that the cost of developing a cancer drug is around $650 million and that companies typically fully recover that cost within a couple of years after approval.
http://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2653012A study sponsored by the AARP finds that specialty drug prices are rising rapidly.
A study in the New England Journal of Medicine finds that reference pricing can lower spending on prescription medications.
Research in the Journal of Health Economics estimates the costs of developing a new medication.
A survey from Manhattan Research examines drug company sales representatives interactions with physicians.
We think generic drugs always contribute to lower spending, but research in the Annals of Internal Medicine finds that generic drugs with a monopoly or in a duopoly have very large price increases, while those in more competitive markets see price declines.
http://annals.org/aim/article/2636750/high-generic-drug-prices-market-competition-retrospective-cohort-studyA study carried by the Journal of the American Medical Association suggests that many newly approved drugs end up having safety issues.
A report from the Blue Cross Blue Shield Association condemns pricing of brand-name drugs as the major driver of drug spending growth.
A report from QuintilesIMS projects “moderate” growth in drug spending through 2021.
Research carried in JAMA reviews the effect of limiting drug rep interactions with physicians on prescriptions.
Express Scripts issues a drug trend report for workers’ compensation insurance.